Go Symbol Lookup
Loading...

Fed Minutes: 'Number of Participants' Express Willingness to Reduce QE in June

United Therapeutics Corp

More

  • April 29- United Therapeutics Corp:. For a summary of rating and price target changes on U.S. companies: Reuters Eikon users, click on RCH/US Reuters 3000 Xtra users, double-click RCH/US Reuters Station users, click. 1568.

  • April 26- United Therapeutics Corp:. Reuters Station users, click. 1568. Reuters Station users, click. 4899.

  • Stocks rose, boosted by gains in shares of materials companies, including iron ore producer Cliffs Natural Resources, and by a drop in weekly jobless claims. **IMPERIAL OIL LTD, $39.78, up 1.6 pct.

  • Stocks rose, boosted by gains in shares of materials companies, including iron ore producer Cliffs Natural Resources, and by a drop in weekly jobless claims. **IMPERIAL OIL LTD, $39.78, up 1.6 pct.

  • Stocks edged higher on Thursday, as investors digested a raft of earnings and a drop in initial jobless claims, though declines in Dow components ExxonMobil and 3 M Co capped the advance. **IMPERIAL OIL LTD, $39.36, up 0.6 pct.

  • April 25- United Therapeutics Corp:. *Q1 revenue $245.1 million versus $204.2 million. *Q1 earnings per share $1.19.

  • *Top official says Cyprus deal is template for euro zone fixes. *Stocks wipe out gains after initial optimism over Cyprus bailout. NEW YORK, March 25- After gaining early on Cyprus's bailout, U.S. stocks fell on Monday on a top euro zone official's comments that Cyprus was a template for handling the region's other debt-strapped countries.

  • *Top official says Cyprus is new template for euro zone fixes. NEW YORK, March 25- U.S. stocks fell on Monday as initial optimism over a bailout for Cyprus gave way to investor worries that the euro zone would shift the burden of aiding weak banks to depositors, bondholders and others instead of to governments and taxpayers.

  • Predictions for FDA Drug Approvals Tuesday, 12 Mar 2013 | 12:13 PM ET

    TheStreet.com reports its investor predictions for FDA drug approvals in 2013: Bad news for Arena Pharmaceuticals, Delcath Systems and Aveo Pharmaceuticals, but Sarepta Therapeutics and Ziopharm are among the winners.